Focusing the FPSC Business on Key Applications and Strengthening Sales

「In the FPSC business, orders for Stirling refrigeration units installed in fuel consumption meters supplied to existing overseas customers continued to be firm, and the Company secured new orders for Stirling refrigeration units for temperature calibrators. In the pharmaceutical and biotechnology sector, which it regards as a medium- to long-term growth area, the Company is proceeding with development toward the November launch of a -86°C portable small freezer box and is also developing sales networks in Japan and overseas.」

「In addition to its existing OEM supply business for refrigeration units, the Company will launch a new -80°C portable small freezer box for the pharmaceutical and biotechnology sectors, drawing on its track record in establishing a cold chain using portable Takeda-Moderna vaccine ultra-low-temperature freezers supplied to the Ministry of Health, Labour and Welfare (-20°C, cumulative shipments of approximately 12,000 units) and on the medical equipment quality certification established by the World Health Organization (WHO) in October 2024, Performance, Quality and Safety (PQS).」

「Drawing on its track record in establishing a cold chain using portable Takeda-Moderna vaccine ultra-low-temperature freezers supplied to the Ministry of Health, Labour and Welfare, with cumulative shipments of approximately 12,000 units, and on the medical equipment quality certification established by the World Health Organization (WHO) in October 2024, Performance, Quality and Safety (PQS), the Company will continue working toward one of the SDGs, “Good Health and Well-Being.”」

「In the FPSC business, revenue and profit declined year on year because shipments decreased as a major overseas customer supplied with standalone refrigeration units adjusted its inventory. As a result, revenue for the interim accounting period was ¥159 million, down 50.6% year on year, and segment profit was ¥7 million, down 90.1% year on year.」

「In the FPSC business, revenue and profit declined year on year because shipments decreased as a major overseas customer supplied with standalone refrigeration units adjusted its inventory. As a result, revenue for the cumulative first quarter was ¥83 million, down 44.9% year on year, and segment profit was ¥3 million, down 92.8% year on year.」

「The Company passed the WHO (World Health Organization) PQS (Performance, Quality and Safety) certification test for medical equipment in late October 2023. It is currently completing the administrative application with WHO headquarters and expects to obtain certification shortly.」

「In the FPSC business, revenue and profit declined year on year because sales of vaccine transport containers for the US market reached a peak and subsequently tapered off as the COVID-19 pandemic subsided. As a result, revenue for the cumulative third quarter was ¥483 million (consolidated revenue of ¥566 million in the same period of the previous year), and segment profit was ¥123 million (consolidated segment profit of ¥139 million in the same period of the previous year).」

「In the FPSC business, revenue and profit declined year on year because sales of vaccine transport containers for the US market reached a peak and subsequently tapered off as the COVID-19 pandemic subsided. As a result, revenue for the cumulative second quarter was ¥323 million (consolidated revenue of ¥387 million in the same period of the previous year), and segment profit was ¥78 million (consolidated segment profit of ¥106 million in the same period of the previous year).」

「In the FPSC business, sales of vaccine transport containers for the United States ran their course as the COVID-19 pandemic subsided, resulting in lower revenue and profit year on year. As a result, revenue in the FPSC business for the cumulative first quarter was ¥151 million, compared with consolidated revenue of ¥228 million in the same period of the previous year, while segment profit was ¥44 million, compared with consolidated segment profit of ¥70 million in the same period of the previous year.」

「In preparation for fourth COVID-19 vaccine doses, the company continued to receive orders for maintenance, or refresh services, for 3,000 vaccine transport containers, bringing the cumulative total to approximately 9,000 units, and completed shipments by December of the previous year.」

「In preparation for fourth COVID-19 vaccine doses, the company continued to receive orders for maintenance, or refresh services, for 3,000 vaccine transport containers, bringing the cumulative total to approximately 9,000 units, and began shipments in October of the previous year.」

「In the FPSC business, demand for large projects associated with COVID-19 vaccinations ran its course, resulting in a substantial year-on-year decline in revenue and profit. Although demand broadened to include services such as refresh services for vaccine transport containers, and revenue was trending higher than before the COVID-19 pandemic, in fiscal 2019, this was not enough to offset the impact of lower profit. As a result, revenue in the FPSC business for the cumulative second quarter of the current consolidated fiscal year was ¥387 million, and segment profit was ¥106 million.」

「In the FPSC business, demand for large projects associated with COVID-19 vaccinations ran its course, resulting in a substantial year-on-year decline in revenue and profit. Although demand broadened to include services such as refresh services for vaccine transport containers, and revenue was trending higher than before the COVID-19 pandemic, in fiscal 2019, this was not enough to offset the impact of lower profit. As a result, revenue in the FPSC business for the cumulative first quarter of the current consolidated fiscal year was ¥228 million, and segment profit was ¥70 million.」

「The company completed shipments in April for a large order of SC-DF25WL deep freezers for COVID-19 vaccines for Takeda Pharmaceutical Company Limited and shipped additional orders from the Ministry of Health, Labour and Welfare in July and September, bringing cumulative shipments since the previous fiscal year to approximately 12,000 units. These products have been widely used to transport and store Moderna vaccines for medical institutions and workplace vaccination venues, among the main vaccination sites. The provision of refresh services for approximately 6,000 units from November onward in preparation for third and subsequent vaccine doses also contributed to performance for the current fiscal year.」

「The company completed shipments in April for a large order of SC-DF25WL deep freezers for COVID-19 vaccines for Takeda Pharmaceutical Company Limited and shipped additional orders from the Ministry of Health, Labour and Welfare in July and September. As a result, revenue in the FPSC business for the cumulative third quarter of the current consolidated fiscal year was ¥2,024 million, an increase of ¥1,746 million year on year, or approximately 7 times the previous year's level, while segment profit was ¥836 million, an increase of ¥786 million, or approximately 17 times the previous year's level.」

「The company completed shipments in April for a large order of SC-DF25WL deep freezers for COVID-19 vaccines for Takeda Pharmaceutical Company Limited and shipped the additional order from the Ministry of Health, Labour and Welfare in July. As a result, revenue in the FPSC business for the cumulative second quarter of the current consolidated fiscal year was ¥1,817 million, an increase of ¥1,659 million year on year, or approximately 12 times the previous year's level, while segment profit was ¥807 million, an increase of ¥781 million, or approximately 31 times the previous year's level. Cash outflows for the acquisition of property, plant and equipment totaled ¥153 million, including investment in FPSC manufacturing equipment and improvements to facilities such as air-conditioning equipment.」

「The company completed shipments in the first quarter of the current consolidated fiscal year for a large order of SC-DF25WL deep freezers for COVID-19 vaccines for Takeda Pharmaceutical Company Limited. Revenue in the FPSC business for the cumulative first quarter was ¥1,142 million, an increase of ¥1,072 million year on year, or approximately 16 times the previous year's level, while segment profit was ¥539 million, an increase of ¥524 million, or approximately 38 times the previous year's level. The company also received a new order from and entered into an agreement with the Ministry of Health, Labour and Welfare for its SC-DF25WL deep freezers for COVID-19 vaccines, as follows. Total amount ¥300 million (base price) Delivery schedule July 2021 (scheduled)」

「In addition to 5,000 units ordered by Takeda Pharmaceutical Company Limited, the company received an additional order for 5,000 units from the Ministry of Health, Labour and Welfare, bringing cumulative orders for SC-DF25WL, deep freezers for COVID-19 vaccines, to 10,000 units. To fulfill these large orders, the company invested in manufacturing equipment and entered a production ramp-up phase in November 2020 in cooperation with local companies, mainly in the Tsubame-Sanjo area. It completed delivery of the 5,000 units ordered by the Ministry of Health, Labour and Welfare during the current consolidated fiscal year.」

「Takeda Pharmaceutical Company Limited and the company entered into the following basic agreement for the company's SC-DF25WL, a deep freezer for Moderna's COVID-19 vaccines. Model number SC-DF25WL Quantity 5,000 units Delivery schedule Scheduled for February-April 2021」

「① Capital for investment in manufacturing equipment for the FPSC business ② Capital for investment in personnel involved in the development and manufacturing of the FPSC business」

「Regarding the business related to FPSC, the new cooling technology (free-piston Stirling cooler), the company aims to expand market share by strengthening sales engineering, deepening customer relationships and applying successful cases across the four priority fields of chemicals and energy, measurement and environment, pharmaceuticals and biotechnology, and food and distribution.」

「The company will further strengthen sales activities, mainly in Europe and North America, including its first exhibition at one of the world's leading expositions focused on refrigeration technology, to be held in Atlanta, United States, in January 2019.」

「For FPSC, the new cooling technology, the company will focus on the application fields of pharmaceuticals, food logistics, energy and measurement, and will develop products in line with customer companies' needs.」

「For FPSC, the new cooling technology, the company will focus on refrigerated and temperature-controlled transportation and cryogenic applications, centered on cryocoolers capable of cooling to as low as -200°C, and will develop products in line with customer companies' needs.」